Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), is expanding its process development capacity for its mammalian cell business. As part of these efforts, Avid is expanding its state-of-the-art laboratories which could support an additional $20 million in annual process development revenue, doubling the company’s current process development capacity. The company estimates that this expansion will cost approximately $6 million and completion is anticipated ...